-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33

Benzinga·09/03/2026 21:11:16
語音播報
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.